Axsome Therapeutics Stock Price, News & Analysis (NASDAQ:AXSM)

Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."

Axsome Therapeutics Inc (NASDAQ:AXSM) announced its earnings results on Thursday, August, 8th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.31) by $0.10. View Axsome Therapeutics' Earnings History.

Axsome Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, November 8th 2019. View Earnings Estimates for Axsome Therapeutics.

8 brokerages have issued 1 year price objectives for Axsome Therapeutics' stock. Their forecasts range from $25.00 to $48.00. On average, they anticipate Axsome Therapeutics' share price to reach $33.2857 in the next year. This suggests a possible upside of 18.3% from the stock's current price. View Analyst Price Targets for Axsome Therapeutics.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Axsome Therapeutics.

News articles about AXSM stock have trended somewhat negative recently, InfoTrie reports. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Axsome Therapeutics earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Axsome Therapeutics.

Axsome Therapeutics saw a decrease in short interest during the month of August. As of August 15th, there was short interest totalling 5,914,300 shares, a decrease of 5.0% from the July 15th total of 6,226,400 shares. Based on an average daily volume of 1,140,000 shares, the short-interest ratio is currently 5.2 days. Approximately 28.5% of the shares of the stock are sold short. View Axsome Therapeutics' Current Options Chain.

Some companies that are related to Axsome Therapeutics include Blueprint Medicines (BPMC), The Medicines (MDCO), United Therapeutics (UTHR), Mirati Therapeutics (MRTX), FibroGen (FGEN), Nektar Therapeutics (NKTR), Allakos (ALLK), Evotec (EVTCY), Alkermes (ALKS), Global Blood Therapeutics (GBT), Taro Pharmaceutical Industries (TARO), BridgeBio Pharma (BBIO), Arrowhead Pharmaceuticals (ARWR), Emergent Biosolutions (EBS) and Reata Pharmaceuticals (RETA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Dicerna Pharmaceuticals (DRNA), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), Amarin (AMRN), Sarepta Therapeutics (SRPT), Synergy Pharmaceuticals (SGYP), SCYNEXIS (SCYX), Zynerba Pharmaceuticals (ZYNE), Anavex Life Sciences (AVXL) and Progenics Pharmaceuticals (PGNX).

(AXSM) raised $52 million in an IPO on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. acted as the underwriters for the IPO and Brean Capital was co-manager.

Axsome Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.91%), VHCP Management III LLC (4.68%), Vanguard Group Inc. (3.35%), VHCP Management II LLC (2.59%), Invesco Ltd. (2.35%) and Price T Rowe Associates Inc. MD (1.68%). Company insiders that own Axsome Therapeutics stock include Mark Coleman, Mark E Saad and Nick Pizzie. View Institutional Ownership Trends for Axsome Therapeutics.

AXSM stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Morgan Stanley, Jane Street Group LLC, Parametric Portfolio Associates LLC and Sio Capital Management LLC. View Insider Buying and Selling for Axsome Therapeutics.

AXSM stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Price T Rowe Associates Inc. MD, VHCP Management III LLC, VHCP Management II LLC, Vanguard Group Inc., Renaissance Technologies LLC, Nuveen Asset Management LLC and Bank of New York Mellon Corp. Company insiders that have bought Axsome Therapeutics stock in the last two years include Mark Coleman, Mark E Saad and Nick Pizzie. View Insider Buying and Selling for Axsome Therapeutics.

Shares of AXSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AXSM stock can currently be purchased for approximately $28.13.

Axsome Therapeutics has a market capitalization of $968.23 million. The company earns $-30,970,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis. Axsome Therapeutics employs 29 workers across the globe.View Additional Information About Axsome Therapeutics.

The official website for Axsome Therapeutics is http://axsome.com/.

Axsome Therapeutics' mailing address is 25 BROADWAY 9TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-332-3241.